New Strategies for Targeting Solid Tumors and the Tumor Microenvironment

One of the biggest challenges for cancer therapeutics, is the targeting of solid tumors. Poor tumor tissue penetration and the heterogeneous distribution have limited the clinical efficacy of therapeutic antibodies. Striking advances in bispecific/multispecific antibodies, T cell engagers and antibody-drug conjugates are now leading the way in oncology discovery, with new strategies to target solid tumors and the tumor microenvironment. This year’s PEGS Boston will present the latest and hottest in antibody-based therapies for cancer, highlight the emerging and new-again targets, as well as showcase the exciting resurgence of antibody-drug conjugates as a hot therapeutic modality. Together, the 3 conferences in this stream will present a comprehensive look at strategies driving toward clinical success.

Conferences Include:

May 15-16

Antibodies for Cancer Therapy

May 16-17

Emerging Targets for Oncology and Beyond

May 18-19

Driving Clinical Success in Antibody Drug Conjugates

Keynote Presentations:

Antibody Therapeutics in Early Clinical Development: Format, Target, and Disease Trends
Janice M. Reichert, PhD, Chief Operating Officer, The Antibody Society

Targeting ROR1 with Antibody-Based Cancer Therapy
Christoph Rader, PhD, Professor, Immunology and Microbiology, UF Scripps Biomedical Research, University of Florida

Trastuzumab Deruxtecan – Successful ADC Development from Payload Selection to Multi-Indication Approval
Gerold Meinhardt, MD, PhD, Vice President – Asset & Portfolio Management, Global Team Lead, DS-8201/ENHERTU, Daiichi Sankyo, Inc.

Mirvetuximab Soravtansine: A Novel FR Alpha-Targeted ADC for Platinum-Resistant Ovarian Cancer
Elisabeth Diver, MD, Medical Director, ImmunoGen

2025 PROGRAMS

View By:

• Display of Biologics
• Engineering Antibodies
• Machine Learning for Protein Engineering

• Antibodies for Cancer Therapy
• Emerging Targets for Oncology & Beyond
• Driving Clinical Success in Antibody-Drug Conjugates

• TS: Intro to Multispecific Antibodies
• Advancing Multispecific Antibodies
• Engineering Bispecific and Multifunctional Antibodies

• Advances in Immunotherapy
• Engineering Cell Therapies
• Next-Generation Immunotherapies

• Difficult-to-Express Proteins
• Optimizing Protein Expression
• Maximizing Protein Production Workflows

• ML and Digital Integration in Biotherapeutic Analytics
• Biophysical Methods
• Characterization for Novel Biotherapeutics

• TS: Intro to Immunogenicity
• Predicting Immunogenicity with AI/ML Tools
• TS: Introduction to Bioassay Development and Analysis

• Biologics for Immunology Indications
• Radiopharmaceutical Therapies
• Next-Generation Immunotherapies

• ML and Digital Integration in Biotherapeutic Analytics
• Predicting Immunogenicity with AI/ML Tools
• Machine Learning for Protein Engineering